Medincell SA
PAR:MEDCL
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
5.92
18.64
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one MEDCL stock under the Base Case scenario is 26.36 EUR. Compared to the current market price of 17.42 EUR, Medincell SA is Undervalued by 34%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Medincell SA
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for MEDCL cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Medincell SA
Balance Sheet Decomposition
Medincell SA
Current Assets | 27.3m |
Cash & Short-Term Investments | 19.5m |
Receivables | 6.7m |
Other Current Assets | 1.1m |
Non-Current Assets | 9.7m |
Long-Term Investments | 1.8m |
PP&E | 5.4m |
Intangibles | 2.5m |
Current Liabilities | 16.5m |
Accounts Payable | 1.8m |
Accrued Liabilities | 3.2m |
Other Current Liabilities | 11.5m |
Non-Current Liabilities | 61.3m |
Long-Term Debt | 52.8m |
Other Non-Current Liabilities | 8.5m |
Earnings Waterfall
Medincell SA
Revenue
|
9m
EUR
|
Cost of Revenue
|
-2.3m
EUR
|
Gross Profit
|
6.8m
EUR
|
Operating Expenses
|
-27.6m
EUR
|
Operating Income
|
-20.8m
EUR
|
Other Expenses
|
-4.2m
EUR
|
Net Income
|
-25m
EUR
|
Free Cash Flow Analysis
Medincell SA
EUR | |
Free Cash Flow | EUR |
MEDCL Profitability Score
Profitability Due Diligence
Medincell SA's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
Score
Medincell SA's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
MEDCL Solvency Score
Solvency Due Diligence
Medincell SA's solvency score is 31/100. The higher the solvency score, the more solvent the company is.
Score
Medincell SA's solvency score is 31/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MEDCL Price Targets Summary
Medincell SA
According to Wall Street analysts, the average 1-year price target for MEDCL is 22.29 EUR with a low forecast of 18.48 EUR and a high forecast of 25.2 EUR.
Dividends
Current shareholder yield for MEDCL is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
MEDCL Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
MedinCell SA is a pharmaceutical company, which engages in the development of injectable products in therapeutic areas. The company is headquartered in Jacou, Occitanie and currently employs 150 full-time employees. The company went IPO on 2018-10-08. The firm is focused on the development of therapeutic solutions with worldwide access. The firm works on both for-profit and non-profit projects, in collaboration with partners ranging from pharmaceutical corporations to physicians, from biotechnology firms to academics and foundations. Its range of products consists of three products in development phase: mdc-IRM, a subcutaneous injection in phase III clinical study for the treatment of schizophrenia; mdc-CWM, an intra-articular injection in phase II clinical study for the treatment of post-surgical pain and inflammation; mdc-TJK, a subcutaneous injection for the treatment of schizophrenia, as well as a number of other products that are in the research phase, such as mdc-WWM, which is a subcutaneous injection for contraception, and mdc-ELK, a subcutaneous injection for the treatment of depression, among others.
Contact
IPO
Employees
Officers
The intrinsic value of one MEDCL stock under the Base Case scenario is 26.36 EUR.
Compared to the current market price of 17.42 EUR, Medincell SA is Undervalued by 34%.